Zobair Younossi, MD, MPH, is chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System.

Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework

Lifestyle intervention remains the foundation of care in 

metabolic dysfunction–associated steatotic liver disease (MASLD)

, but the delivery may be more effective if given as a structured, prescription-like intervention, outsourcing appropriate clinical support.

“In my view, lifestyle is the foundation, you have to always start with lifestyle, because that is just not, you know, eat less and exercise, that's just, that's not going to work,” Zobair Younossi, MD, MPH, chairman of the Global NASH Council and professor of medicine and chairman of the Global Center for Liver Outcomes & Policy Research at Georgetown University School of Medicine, told HCPLive. “You have to really do this in a way that's similar to a prescription, so you're giving patients adequate support, even a nutrition consult available, or dietitian, to make sure not only they're going to eat right, or what is eating right, eating right is not just cutting calories, but also avoiding ultra-processed food, eating a diet that's similar to a Mediterranean diet.”

He noted that Mediterranean-style dietary patterns should be understood as diets rich in fruits and vegetables, with protein sourced from healthier options, while minimizing ultra-processed food intake.

Alcohol consumption, even in moderation, may be harmful in MASLD, particularly given patterns of binge drinking that can exacerbate liver injury. Smoking cessation and increased physical activity, including resistance training to support muscle health,were also emphasized as key components of care.

Expanding Pharmacologic Options in MASLD and MASH

Beyond lifestyle intervention, pharmacologic therapies are increasingly shaping the MASLD and metabolic dysfunction–associated steatohepatitis (MASH) treatment landscape.

In the United States, approved therapies include resmetirom, a thyroid hormone receptor-β agonist, and semaglutide, a GLP-1 receptor agonist. These agents reflect a broader shift toward targeting metabolic dysfunction underlying hepatic steatosis and fibrosis.

Metabolic Burden and Symptom Underrecognition in MASLD

Hepatic steatosis is increasingly recognized as a surrogate marker of systemic metabolic dysfunction, with implications that extend beyond the liver. Patients with MASLD face increased risks of progression to MASH and cirrhosis, as well as cardiometabolic comorbidities including cardiovascular disease, type 2 diabetes, and chronic kidney disease.

Fatigue remains one of the most common but underrecognized symptoms in MASLD, despite its impact on quality of life.

EXCEL Trial Demonstrates Improvements in Hepatic Steatosis and Fatigue

Emerging clinical data from the phase 4 EXCEL trial support a multidimensional approach to MASLD treatment outcomes.

The double-blind, randomized, placebo-controlled study evaluated essential phospholipids (EPL) added to standard of care in patients with MASLD and metabolic comorbidities. EPL met its primary endpoint, demonstrating a statistically significant reduction in hepatic steatosis compared with placebo, as measured by controlled attenuation parameter (CAP) on FibroScan.

Improvements in hepatic fat were observed as early as 3 months and remained significant during follow-up. At 6 months, the least-squares mean difference (LSMD) in CAP score was −14.81 dB/m (SE, 6.63; 95% Confidence Interval [CI], −27.89 to −1.72;  

The trial also included patient-reported outcomes. EPL was associated with a statistically significant improvement in fatigue at 6 months compared with placebo (LSMD, 0.31; SE, 0.13; 95% CI, 0.04–0.58;

= .0229). Improvements in HbA1c were also observed (LSMD, −0.55%; SE, 0.20; 95% CI, −0.95 to −0.15; 

= .0069), suggesting broader metabolic effects beyond hepatic endpoints.

While quality-of-life improvements did not reach statistical significance, numerical trends favored EPL across multiple time points.

A Multi-Domain Framework for Evaluating MASLD Outcomes

Experts emphasize that MASLD should be evaluated across three domains: clinical outcomes such as progression to cirrhosis, patient-reported outcomes including fatigue and quality of life, and economic outcomes reflecting healthcare utilization and societal burden.

“At the end, it looks like we do have good drugs, not perfect drugs for treatment of MASH, but pretty good drugs, and we're going to have better drugs in the near future,” Younossi said. “When you look at what a drug works or an intervention works, it's absolutely important to not only look at clinical outcomes but also patiently reported.”

Editor’s Note: Younossi reports relevant disclosures with Boehringer Ingelheim, Ipsen, Gilead Sciences, BMS, GSK, NovoNordisk, Siemens, Madrigal Pharmaceuticals, Merck, and Abbott.

Stefan N, Hartleb M, Fan J, et al. Effect of Essential Phospholipids in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial. 

Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. 

https://doi.org/10.1016/S0140-6736(24)01811-7

Videos

Zobair Younossi, MD, explains how lifestyle, drugs, and EXCEL data show steatosis and fatigue improvements in MASLD.


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Lisa Horne, director of marketing at the Food Allergy & Anaphylaxis Connection Team (FAACT).

FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life

When Lisa Horne, director of marketing at the Food Allergy & Anaphylaxis Connection Team (FAACT), described the premise behind 

The series, a 4-episode microdrama produced in partnership with Genentech and Novartis, follows a group of young adults with 

navigating a night out in New York City. Finding a restaurant. Planning ahead. Running into an ex. Catching up at the end of the evening. Although simple enough for most people, for someone managing multiple food allergies, each of those moments carries an additional layer of preparation, self-advocacy, and social calculation that rarely surfaces during a clinical appointment.

"Food allergy education often focuses on the medical side—the diagnosis, how to manage and treat the food allergy—but there's not a lot of focus on everyday life: how to navigate dining out, dating, being on sports teams, going to school,” Horne told 

The participants in the series are not actors. They are 5 young adults (aged 18 to 23 years) with varying combinations of food allergies to peanuts, tree nuts, milk, eggs, and sesame, among others. Their stories shaped the episodes directly.

What emerged were themes that cut across all of their backgrounds: feeling different, managing anxiety, and the constant work of advocating for themselves in social situations. Horne noted 1 moment that stood out: a cast member who routinely eats before going out to a restaurant because they cannot be certain the food there will be safe.

"It's one of those situations where if you are a parent or a guardian or you yourself have food allergies, you watch it and you feel surprised, yet not surprised at the same time," Horne said. "Because it resonates with you. And then you realize, ‘I’m not alone."‘

For allergists and other clinicians, the series surfaces conversations that often do not happen in exam rooms. Horne said that patients tend to focus on symptoms and treatment during appointments, and clinicians follow their lead. Topics like dating, kissing, sexual activity, and social embarrassment rarely come up — even though something as common as a kiss can trigger a life-threatening anaphylactic reaction.

“I think that individuals are embarrassed and afraid to discuss [these types of reactions],” Horne said. “Asking these broader...and more personal questions to open that dialog and bridge that gap between diagnosis, management, and treatment…opens the door to those conversations to give better care and a better quality of life to those individuals.”

 in clinical settings. The series can be shared through patient portals, screened in waiting rooms, or used as a follow-up resource after appointments. She said its value lies in making patients feel seen and in creating an opening for conversations that may not arise organically during a visit.

She offered a simple prompt for clinicians to surface challenges that might otherwise go unspoken: “It could really be as open-ended as: ‘

How are food allergies affecting your daily life?”’

Food Allergies in the City is available at foodallergyawareness.org. Genentech Inc. and Novartis Pharmaceuticals Corporation sponsored the series.

Living with Food Allergies - Food Allergies in the City - Food Allergies in the City | FAACT. Foodallergyawareness.org. Published 2026. Accessed June 23, 2026. 

https://www.foodallergyawareness.org/living-with-food-allergies/food-allergies-in-the-city/

A new 4-part microdrama series developed with real young adults living with food allergies aims to bridge the gap between clinical management and everyday life.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life 

Elaine Siegfried, MD, is a professor of Pediatrics and Dermatology at the Saint Louis University School of Medicine and is the director of Pediatric Dermatology at SSM Health Cardinal Glennon Children's Hospital in St. Louis, Missouri.

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

 in Nashville, Tennessee, featured a wide array of unique sessions designed to highlight the most important developments in the atopic dermatitis landscape of 2026, including phase 3 data, upcoming news, clinical pearls, and more.

One such session was titled ‘Practice Pearls for Pediatric AD Spotlight CE Symposium.’ In an interview with 

s editorial staff at RAD, Elaine Siegfried, MD, a board-certified pediatrician and internationally recognized pediatric dermatologist, spoke about some of the most notable highlights of her session at the conference.

Siegried is known for her role as a professor of Pediatrics and Dermatology at the Saint Louis University School of Medicine. She also serves as director of Pediatric Dermatology at SSM Health Cardinal Glennon Children's Hospital in St. Louis, Missouri. Siegfried was asked about several important questions from her session, highlighting key clinical pearls for clinicians working in the field of dermatology.

The following Q&A highlights Siegfried’s responses to these inquiries regarding her presentation at RAD 2026:

How would you define the current standard of care for pediatric atopic dermatitis in 2026, and where do you believe the field has evolved most significantly in the past few years?

Well, that's a big question. You always evaluate the patient based on severity, and then you match the treatment based on their severity, and then a variety of other factors. You have to take into account parameters that are impacting them: tolerating treatment, how well are they sleeping, how's it impacting the family, those sort of things…Obviously we've got biologic systemic treatments, and now we have small molecules. I think one of the most important things that's happened in the last couple of decades is that children are included; they used to be excluded from trials, period, but now they're included, and they're included earlier, so it helps get us the data that we need.

Despite the growing number of obviously available therapies, what do you see as the most pressing unmet needs in the pediatric space?

Well, even though we have pediatric data, the data always follows adult data. Often that's by quite a long period of time. And another big unmet need is really children under the age of six months. That's when atopic dermatitis presents in early infancy, and we are at a real loss for being able to start children on, frankly, treatments other than topical corticosteroids.

 How are you approaching treatment sequencing among topical therapies, biologics, JAK inhibitors, and what factors most impact this decision?

You always start with topical therapy, and there's a mechanism to do that. Just paying attention to the over-the-counter topical treatments that they're using, then adding systemic treatment, and then deciding when a child is beyond topical corticosteroids and needs a steroid-sparing agent. Then when they fail topical therapy, and there are a lot of reasons that contribute to failing topical therapy, from just not being able to do it. A big one is cost, frankly, and what you can get access to, and then not being able to tolerate it, and having severity that's beyond being able to treat it topically.

I think it's really important to recognize, for children who have atopic dermatitis, the most vulnerable percentage of the population, these are kids that have unrecognized nutritional or immune deficiencies. I think it's really important to thoroughly evaluate them, but the most important thing to start with there is how they're growing. I think a lot of dermatology providers, who especially who aren't trained in pediatrics, don't pay any attention to how they're growing. You've got to look at their growth curve always, and people who get children who aren't growing well is a very vulnerable subset.

 Has the availability of advanced therapies changed your threshold for escalating treatment in these pediatric patients?

Absolutely. Having the newer non-steroidals particularly, I think that topical corticosteroid use is going to be significantly impacted in the next 10 years. It's going to require a lot of education, because those drugs have been around for such a long time, and frankly, because they're so cheap. But it's so important to monitor quantities that patients are using, and if they're beyond safe quantities and frequency, then they're going to be able to move on to non-steroids, which is great.

To what extent are we moving toward a sort of disease modification approach in pediatric atopic dermatitis, and what evidence do you find most can be done in support of that kind of thing?

 Well, certainly, we don't have the amount of data that we'd like about disease modification; it's certainly a great theory, but our pharmaceutical industry friends are paying a lot of attention to looking at long-term remission, both on drug and especially off drug. That data is coming, and I think it’s exciting and it's going to be impactful.

Are there specific pediatric atopic dermatitis phenotypes or patient populations that remain particularly challenging to manage, despite recent therapeutic advances?

 The subset that I alluded to is the kids that aren't growing well and that have moderate to severe disease that aren't growing well. Really, they deserve laboratory evaluation. A lot of them have sky-high total IgE levels, which puts them in a different immunologic category that we don't really understand very well. Then the subset that has marked eosinophilia, so the definition of hypereosinophilia is 1500 absolute eosinophil count three times in six months, and if you have that, that is the definition of hypereosinophilic syndrome. Those are kids who are very vulnerable and at risk, even with our current treatments. I think it's really important to recognize that subset.

Siegfried had no relevant financial disclosures of note.

Siegfried E, Eichenfield L. Practice Pearls for Pediatric AD Spotlight CE Symposium. Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.

Articles

Pediatric atopic dermatitis care in 2026 emphasizes severity-based, patient- and family-centered assessment, incorporating sleep, tolerability, and psychosocial burden alongside disease extent. Therapeutic options now span optimized topical regimens, steroid-sparing nonsteroidals, biologics, and small-molecule agents, supported by earlier pediatric trial inclusion. Key gaps persist, particularly for infants <6 months and delayed pediatric-label data relative to adults. Earlier escalation thresholds are emerging, driven by safety monitoring of corticosteroid exposure and access barriers. Attention to growth trajectories and immunologic outliers informs risk stratification.

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Bo Lieng, MD, PhD | Image Credit: Corxel Pharmaceuticals

CX11, an investigational oral small-molecule GLP-1 receptor agonist, has displayed continued and consistent weight reduction in patients with 

On June 23, 2026, parent company Corxel Pharmaceuticals reported positive top-line findings from a phase 2 trial of CX11 in adults with obesity or overweight with ≥1 weight-related comorbidity. The company said the trial met its primary endpoints and reported weight loss of up to 11.5% at 36 weeks.

“We are delighted with these positive U.S. Phase 2 results, which are consistent with the competitive profile established in the China Phase 3 program,” Bo Liang, MD, PhD, chief medical officer of Corxel, said in a statement. “Together, these datasets reinforce our confidence in CX11 and our conviction to offer patients around the world an effective and highly tolerable option with dosing flexibility.”

The phase 2 trial enrolled 246 US adults with obesity, defined as a body mass index of ≥30 kg/m², or overweight, defined as a body mass index of 27 - <30 kg/m² with ≥1 weight-related comorbidity. Participants were randomized in a 1:1:1:1:1 ratio to receive once-daily CX11 at 120 mg, CX11 at 160 mg, CX11 at 200 mg with slow titration, CX11 at 200 mg with fast titration, or placebo for 36 weeks.

At week 36, Corxel reported up to 11.5% weight loss among participants with obesity receiving CX11. The company also reported ongoing weight reduction at a consistent rate, without evidence of a plateau during the 36-week double-blind treatment period.1 However, the announcement did not provide placebo-adjusted weight-loss estimates, confidence intervals, P values, prespecified endpoint definitions, or weight-loss results by each dose and titration cohort. Those details will be important for interpreting the magnitude and consistency of the response across dosing strategies.

Gastrointestinal adverse events were the most frequently reported safety findings in the phase 2 trial, consistent with the broader incretin-based obesity treatment class. Across CX11 dosing cohorts, Corxel reported nausea rates of 33% to 34%, vomiting rates of 12% to 16%, diarrhea rates of 4% to 12%, and constipation rates of 2% to 12%. The company described these events as generally mild to moderate in severity and reported no severe cases of nausea, vomiting, diarrhea, or constipation.

Corxel also reported gastrointestinal adverse events occurred mainly during dose escalation and decreased during the maintenance period. The overall treatment discontinuation rate attributed to gastrointestinal adverse events was 5.0%.

The company stated no hepatic safety signal was observed in the US phase 2 study or in a China phase 3 program conducted with partner Vincentage Pharma. Corxel reported that ≥1500 participants have been studied across CX11 clinical studies to date, with no hepatic safety signal identified.

Oral GLP-1 Agonist Context and Next Steps

CX11 is being developed as an oral small-molecule GLP-1 receptor agonist for weight management. GLP-1 receptor agonism is an established therapeutic pathway in obesity pharmacotherapy, and injectable incretin-based agents have demonstrated substantial weight loss in large phase 3 trials. Previous trials, like STEP 1, showed that once-weekly semaglutide 2.4 mg is associated with greater mean weight reduction than placebo among adults with overweight or obesity. In SURMOUNT-1, once-weekly tirzepatide was associated with substantial body weight reduction across studied doses in adults with obesity or overweight. These data provide a contemporary efficacy and tolerability benchmark for investigational agents in this class.

Corxel’s announcement positions CX11 as a candidate for further evaluation in global pivotal studies, but the evidence remains limited to company-reported top-line data for the US phase 2 trial. The China phase 3 findings referenced in the announcement were not detailed in the release, and the US results have not yet been presented with full statistical methods or peer-reviewed data in the source material. Additional reporting from phase 3 studies will be needed to clarify dose selection, durability of weight loss beyond 36 weeks, comparative tolerability, cardiometabolic effects, and longer-term safety.

Corxel Pharmaceuticals. Corxel Pharmaceuticals reports positive top-line results from Phase 2 trial of CX11 in obese and overweight U.S. adults. Published June 23, 2026. Accessed June 23, 2026. 

https://www.corxelbio.com/en/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-us-adults

Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. 

. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. 

. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

Corxel reported positive US phase 2 top-line data for CX11, an oral small-molecule GLP-1 receptor agonist, in 246 adults with obesity or overweight plus comorbidity. Once-daily dosing across four CX11 regimens over 36 weeks yielded up to 11.5% weight loss in participants with obesity, with continued decline and no apparent plateau. Gastrointestinal adverse events were most common, generally mild-to-moderate, clustered during titration, and led to 5.0% discontinuation. Key efficacy and safety details remain undisclosed pending fuller data.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports

From Label to Etiology: Applying the 2026 AACE Framework

Experts conclude by emphasizing that the 2026 AACE classification algorithm is a call for clinicians to pause, reassess presumed type 2 diabetes, and recognize that getting the etiology right is foundational to optimizing downstream treatment.

In the closing segment, Samson reiterates that the differential diagnosis for adult-onset diabetes is far broader than the traditional assumption that most patients have type 2 diabetes. She emphasizes that clinicians should not simply accept a preexisting type 2 diabetes label when patients establish care, particularly if the disease course does not align with the expected phenotype. Instead, the 2026 AACE algorithm encourages a systematic reassessment of diagnosis when glycemic patterns, insulin requirements, weight trajectory, or associated comorbidities raise concern.

Samson notes that individuals who clearly do not fit a typical type 2 phenotype—whether because of autoimmunity, pancreatic disease, endocrinopathy, or genetic features—should be referred for endocrinology evaluation and more detailed classification.

Umpierrez reflects on his decades of practice in diabetes and endocrinology and candidly acknowledges how often he now questions whether earlier patients may have been misclassified as having type 2 diabetes. He underscores that misclassification of adult-onset type 1 diabetes as type 2, pancreatic diabetes, MODY, or cortisol-mediated diabetes is not merely academic; it can profoundly alter downstream treatment decisions, risk for acute complications such as diabetic ketoacidosis, and the trajectory of chronic complications.

In his view, the 2026 AACE classification algorithm provides a practical, clinically oriented framework that can help busy clinicians recognize when additional testing, imaging, or specialist referral is warranted.

Together, Samson and Umpierrez characterize the new algorithm as an “invitation to pause”—a structured prompt to ask whether the current diagnosis truly explains the patient’s presentation and treatment response. By embedding classification logic alongside therapeutic guidance, the 2026 AACE algorithm aims to ensure that the right diagnosis underpins decisions about pharmacologic therapy, technology use, and long-term risk reduction.

The experts conclude that widespread adoption of this approach has the potential to improve diagnostic accuracy, individualize care, and ultimately enhance outcomes for adults living with diabetes who might otherwise be managed under an oversimplified label of type 2 diabetes.

Learn how clinicians spot uncommon diabetes causes—from pancreatic disease and MODY to steroids, transplants, and checkpoint inhibitors—before treatment.

Video Series

Explore signs of uncommon diabetes—from pancreatic disease and MODY to steroid, transplant, and checkpoint-inhibitor autoimmune causes.

How the 2026 AACE Algorithm Broadens the Lens on Diabetes

Aboul-Fettouh recounts a case in which an incidental skin examination revealed longstanding, undertreated AA in a patient who had been told no effective therapy existed, illustrating how the new generation of JAK inhibitors can restore both hair and hope.

A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease

Learn key clues that diabetes isn’t type 2, and how autoantibody tests plus C‑peptide guide accurate adult type 1/LADA diagnosis.

Hypercortisolism in Refractory Diabetes, CATALYST Data

Aboul-Fettouh reviews the 3 FDA-approved JAK inhibitors for alopecia areata, highlighting key differentiators-age indication, dosing convenience, renal and hepatic adjustment requirements, and the potential to switch agents when initial therapy fails to achieve adequate regrowth.

Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib

Spot hidden type 1/LADA in overweight adults: learn key red flags, and how autoantibodies plus C-peptide guide accurate diagnosis.

Red Flags for Misdiagnosed Type 2, When to Order Antibodies and C‑Peptide

Raghuveer Vedala, MD, is a clinical physician at the Norman Regional Health System.

In the final segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity

In the fourth segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: GLP-1s in Conditions Beyond Obesity

In the third segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: The Side Effects of GLP-1s for Obesity

In the second segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

OMA 2026 Recap: Oral Pharmacotherapy for Obesity

In the first segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

Latest News

Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework

FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life

Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD

CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports

From Label to Etiology: Applying the 2026 AACE Framework